OpenAI announced Thursday that it has entered into an agreement to acquire Astral, the company behind popular open source Python development tools such as uv, Ruff, and ty, and integrate the company ...

PYTHON blood could hold the key to the next blockbuster weight loss treatment, scientists say. The reptiles can go months without eating after consuming a massive meal, while still remaining ...

Typically, when people think of dangerous animal encounters, they imagine them happening in remote wild places. In reality, they can happen almost anywhere, including along roadsides and near ...

Scientists have discovered a molecule in python blood that suppresses appetite, potentially leading to a new class of obesity drugs.

OpenAI has announced plans to acquire Astral, integrating its open-source developer tools into the Codex ecosystem to enhance AI agent capabilities.

OpenAI said on Thursday it will acquire Python toolmaker Astral, as the ChatGPT owner looks to strengthen its portfolio against rival Anthropic and gain more share in the artificial intelligence ...

Scientists Were Studying Snake Blood For Other Reasons. What They Found Could Change Obesity Treatment. In A Nutshell Scientists discovered a molecule called pTOS in python blood that surges after ...

Researchers find snake metabolite that suppresses appetite of obese mice ‘without some of side-effects’ of GLP-1 drugs ...

OpenAI acquires Astral, the Python toolmaker, to enhance Codex AI coding assistant as it competes with Anthropic's Claude Code and Cursor.

A cluster near Kalothare Wali Mata temple turned into writhing pythons, but why were several giant snakes gathered together, ...

University of Colorado Boulder researchers have discovered an appetite-suppressing compound in python blood that helps the snakes consume enormous meals and go months without eating yet remain ...

OpenAI's most significant competitors in the AI coding space include Cursor and Anthropic ( ANTHRO ). Cursor is in talks with investors for a funding round that would value the startup at about $50B.